• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Dorbin John W. Jr.

    11/2/23 4:31:52 PM ET
    $ADMP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADMP alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Dorbin John W. Jr.

    (Last) (First) (Middle)
    C/O DMK PHARMACEUTICALS CORPORATION
    11622 EL CAMINO REAL, SUITE 100

    (Street)
    SAN DIEGO CA 92130

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    10/23/2023
    3. Issuer Name and Ticker or Trading Symbol
    DMK PHARMACEUTICALS Corp [ DMK ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    General Counsel
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    No securities are beneficially owned. Exhibit List: Exhibit 24 - Power of Attorney
    No securities are beneficially owned.
    /s/ John W. Dorbin, Jr. 11/01/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ADMP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ADMP

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ADMP
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for ZIMHI issued to ADAMIS PHARMS CORP

      Submission status for ADAMIS PHARMS CORP's drug ZIMHI (ORIG-1) with active ingredient NALOXONE HYDROCHLORIDE has changed to 'Approval' on 10/15/2021. Application Category: NDA, Application Number: 212854, Application Classification: Type 5 - New Formulation or New Manufacturer

      10/18/21 11:55:40 AM ET
      $ADMP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for SYMJEPI issued to ADAMIS PHARMS CORP

      Submission status for ADAMIS PHARMS CORP's drug SYMJEPI (SUPPL-12) with active ingredient EPINEPHRINE has changed to 'Approval' on 06/29/2021. Application Category: NDA, Application Number: 207534, Application Classification: Labeling

      6/30/21 5:11:48 AM ET
      $ADMP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADMP
    SEC Filings

    See more
    • Adamis Pharmaceuticals Corporation filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - DMK PHARMACEUTICALS Corp (0000887247) (Filer)

      2/7/24 5:19:44 PM ET
      $ADMP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adamis Pharmaceuticals Corporation filed SEC Form 8-K: Bankruptcy or Receivership, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - DMK PHARMACEUTICALS Corp (0000887247) (Filer)

      2/5/24 9:00:57 AM ET
      $ADMP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adamis Pharmaceuticals Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - DMK PHARMACEUTICALS Corp (0000887247) (Filer)

      1/31/24 5:17:31 PM ET
      $ADMP
      Biotechnology: Pharmaceutical Preparations
      Health Care